Document is current

Article History

Received: 22 March 2020

Accepted: 25 August 2020

First Online: 20 October 2020

Competing interests

: All disclosures are outside the submitted work. Dr. Friedman reports institutional research support from Bristol Myers Squibb, Genentech and Merck; service on Advisory Board for AstraZeneca; Steering Committee Membership for Genentech and Merck (compensation waived); research support from Merck, outside the submitted work. Dr. Abu-Rustum reports grants from Stryker/Novadaq, grants from Olympus, grants from GRAIL, outside the submitted work. Dr. Aghajanian reports personal fees from Tesaro, personal fees from Immunogen, personal fees from Mateon Therapeutics, personal fees from Cerulean Pharma; grants and personal fees from Clovis; grants from Genentech, grants from AbbVie, grants from Astra Zeneca, outside the submitted work. Dr. Zamarin reports grants from Merck; personal fees from Merck, personal fees from Synlogic Therapeutics, personal fees from Psioxus Therapeutics, personal fees from Biomed Valley Discoveries, personal fees from Tizona Therapeutics, personal fees from ACM Biolabs, personal fees from Tesaro, outside the submitted work; a patent Chimeric Newcastle Disease Virus and uses thereof with royalties paid to Merck, outside the submitted work. Dr. Cadoo reports travel, expenses and institutional support for therapeutic trial from AstraZeneca; institutional support for therapeutic trial from Syndax Pharmaceuticals; travel and expenses from Tessaro, outside of the submitted work. Dr. Diaz is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; a paid consultant to PGDx, 4Paws and Neophore; uncompensated consultant for Merck; prior research support for clinical trials from Merck; equity holder in PGDx, Jounce Therapeutics, Thrive Earlier Detection, and Neophore; equity holder in Amgen (spouse), outside the submitted work. Dr. Leitao is an ad hoc speaker for Intuitive Surgical Inc., outside the submitted work. Dr. Makker reports grants and personal fees from Esai; grants and personal fees from Merck; other from International PI 775-03/E7080-G000-309; Grants from Takeda (MSKCC PI C31004); personal fees from ArQule; grants and personal fees from Karyopharm; grants from AstraZeneca, grants from Lilly; personal fees from IBM Watson, outside the submitted work. Dr. Soslow reports personal fees from Ebix/Oakstone*; personal fees from Cambridge University Press**; personal fees from Springer Publishers**, outside the submitted work. (*Preparation of recorded lectures; **royalties). Dr. Weigelt reports consulting fees from Goldman Sachs (spouse), REPARE Therapeutics (spouse) and Paige.AI (spouse), and service as advisory board member for Roche Diagnostics (spouse), InVicro (spouse), Genentech (spouse), Paige.AI (spouse), Volition RX (spouse), REPARE Therapeutics (spouse) and GRAIL (spouse), outside the submitted work. Dr. Lakhman is a shareholder in Y-mAbs Therapeutics, outside the submitted work. The authors declare no competing interests.